Axovant Sciences Ltd (NYSE:AXON) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.

A number of other equities research analysts also recently issued reports on AXON. Jefferies Group LLC reissued a “buy” rating and issued a $31.00 price target on shares of Axovant Sciences in a research note on Friday, June 9th. Cowen and Company reissued an “outperform” rating and issued a $30.00 price target (up from $22.00) on shares of Axovant Sciences in a research note on Tuesday, June 13th. Oppenheimer Holdings, Inc. boosted their price target on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, June 14th. CIBC boosted their price target on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, June 14th. Finally, BidaskClub raised shares of Axovant Sciences from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Five equities research analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $14.32.

Axovant Sciences (AXON) opened at 6.99 on Tuesday. Axovant Sciences has a 52 week low of $6.55 and a 52 week high of $27.98. The firm has a 50-day moving average of $21.33 and a 200-day moving average of $21.33. The company’s market capitalization is $751.60 million.

Axovant Sciences (NYSE:AXON) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.12). Analysts anticipate that Axovant Sciences will post ($2.33) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “ValuEngine Downgrades Axovant Sciences Ltd (AXON) to Sell” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/28/valuengine-downgrades-axovant-sciences-ltd-axon-to-sell.html.

Several hedge funds have recently made changes to their positions in the stock. FMR LLC grew its holdings in shares of Axovant Sciences by 968.5% in the second quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock valued at $167,794,000 after purchasing an additional 6,558,462 shares in the last quarter. Capital Research Global Investors grew its holdings in shares of Axovant Sciences by 21.8% in the second quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock valued at $80,094,000 after purchasing an additional 619,226 shares in the last quarter. Primecap Management Co. CA grew its holdings in shares of Axovant Sciences by 300.1% in the first quarter. Primecap Management Co. CA now owns 2,878,930 shares of the biotechnology company’s stock valued at $43,011,000 after purchasing an additional 2,159,428 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Axovant Sciences in the second quarter valued at approximately $47,854,000. Finally, State Street Corp grew its holdings in shares of Axovant Sciences by 52.8% in the second quarter. State Street Corp now owns 546,920 shares of the biotechnology company’s stock valued at $12,682,000 after purchasing an additional 188,945 shares in the last quarter.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Stock Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related stocks with our FREE daily email newsletter.